Skip to main content
Erschienen in:

06.11.2020 | original article

Effect of intravitreal anti-vascular endothelial growth factor administration on the vitreomacular interface and retinal morphology in eyes with neovascular age-related macular degeneration

verfasst von: Clara Wernigg, MD, Christopher Schütze, MD, PhD, Prof. Pia-Veronika Vécsei-Marlovits, MD, MBA, Birgit Weingessel, MD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Summary

Background

To assess the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) administration on the vitreomacular interface and retinal morphology in eyes with neovascular age-related macular degeneration (AMD) and to identify morphological markers potentially influencing disease prognosis.

Material and methods

A total of 43 patients (51 eyes) with treatment-naïve neovascular AMD subsequently treated with bevacizumab 1.25 mg (in 0.05 ml of solution) were monitored until month 12 of follow-up. Following a loading dose of three monthly intravitreal anti-VEGF injections, patients were treated as-needed (pro re nata [PRN]). Functional and morphological changes were assessed using spectral domain optical coherence tomography (SD-OCT).

Results

All study eyes showed evidence of an increase in the frequency of geographic atrophy (GA) occurrence during follow-up compared to baseline (n = 23 [45%] at month 12 compared to n = 5 [9.8%] at baseline [p > 0.05]). There was a trend towards more frequent GA in eyes diagnosed with posterior vitreomacular adhesion (PVA) at baseline that developed posterior vitreous detachment (PVD) during follow-up compared to eyes not developing PVD (35% vs. 44% GA, p 0.56).

Conclusions

Alterations of the vitreomacular interface and retinal morphology in patients with neovascular AMD treated with bevacizumab may have a significant effect on prognosis with respect to GA development. Eyes with vitreomacular adhesion at baseline developing GA during follow-up might require more intensive anti-VEGF therapy with a decreased ability to extend treatment intervals. Findings are comparable to eyes treated with other anti-VEGF agents administered for the management of neovascular AMD.
Literatur
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Metadaten
Titel
Effect of intravitreal anti-vascular endothelial growth factor administration on the vitreomacular interface and retinal morphology in eyes with neovascular age-related macular degeneration
verfasst von
Clara Wernigg, MD
Christopher Schütze, MD, PhD
Prof. Pia-Veronika Vécsei-Marlovits, MD, MBA
Birgit Weingessel, MD
Publikationsdatum
06.11.2020
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 2/2021
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-020-00471-5